Last reviewed · How we verify
MBX-400
At a glance
| Generic name | MBX-400 |
|---|---|
| Also known as | ZSM-I-62, NSC D745998, Cyclopropavir (CPV), (Z)-9-{[2,2-bis-(hydroxymethyl)cyclopropylidene] methyl}guanine |
| Sponsor | Microbiotix, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers (PHASE1)
- Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MBX-400 CI brief — competitive landscape report
- MBX-400 updates RSS · CI watch RSS
- Microbiotix, Inc. portfolio CI